The UltraShape procedure is available in 57 countries and over 100,000 patient treatments have been performed worldwide with high patient satisfaction. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software provides a pre-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of liposuction. The UltraShape procedure is performed during a convenient, "walk-in, walk-out" session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments.
The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S. and the Contour Plus system is an investigational product limited by U.S. law to investigational use only.
UltraShape is redefining aesthetic medicine by developing,
manufacturing and marketing innovative non-invasive technologies for body
contouring. The company is dedicated to providing clinically proven safe
and effective solutions that enhance the lives of patients worldwide. The
UltraShape proprietary non-invasive body contouring technology is based on
focused ultrasound that targets and selectively disrupts fat cells without
affecting surrounding structures. Founded in 2000, UltraShape is a
privately held and venture backed company. The UltraShape system is not
approved by the FDA for marketing in the United States. Fo
|SOURCE UltraShape Ltd.|
Copyright©2008 PR Newswire.
All rights reserved